Skip to main content

Advertisement

ADVERTISEMENT

Videos

Rahul Banerjee, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates & Updates meeting, Rahul Banerjee, MD, participated in a debate in which he argued against the use of CAR T-cell therapy in earlier lines of therapy among patients with multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology
Amrita Krishnan, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates & Updates meeting, Amrita Krishnan, MD, argued for the value of considering autologous stem cell transplantation for certain patients over the age of 65, emphasizing the benefit of assessing frailty as a complex and...
At the 2024 Great Debates &...
07/28/2024
Oncology
Murali Janakiram, MD, MS
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates & Updates meeting, Murali Janakiram, MD, MS, participated in a debate about the value of MRD assessment in the treatment and management of multiple myeloma.
At the 2024 Great Debates &...
07/28/2024
Oncology

Advertisement

Pinkal Desai, MD
Videos
07/28/2024
Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.
Pinkal Desai, MD, discusses risk stratification, restructured disease classifications, and current treatment options for patients with low and intermediate-risk myelodysplastic syndrome at the 2024 Great Debates & Updates meeting.
Pinkal Desai, MD, discusses risk...
07/28/2024
Oncology
Inhye Ahn, MD
Videos
07/28/2024
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next steps for investigating applications of pirtobrutinib in the current treatment paradigm for patients with chronic lymphocytic leukemia.
Inhye Ahn, MD, discusses next...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Tycel Phillips, MD
Videos
07/28/2024
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the latest updates and developments in both the frontline and relapsed/refractory treatment landscape for patients with mantle cell lymphoma.
Tycel Phillips, MD, reviews the...
07/28/2024
Lymphoma, Leukemia & Myeloma Network

Advertisement

Tycel Phillips, MD
Videos
07/28/2024
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates & Updates meeting, Tycel Phillips, MD, participated in a debate about the role of non-chemotherapy regimens for the treatment of patients with newly diagnosed mantle cell lymphoma.
At the 2024 Great Debates &...
07/28/2024
Lymphoma, Leukemia & Myeloma Network
Paula Rodríguez-Otero, MD
Videos
07/27/2024
Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.
Paula Rodríguez-Otero, MD, highlights results supporting the use of daratumumab plus bortezomib, lenalidomide and dexamethasone as a standard of care treatment for transplant-eligible patients with newly diagnosed multiple myeloma.
Paula Rodríguez-Otero, MD,...
07/27/2024
Oncology
Prithviraj Bose, MD
Videos
07/25/2024
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares results from an ongoing study that demonstrate that zilurgisertib as monotherapy or in combination with ruxolitinib had a favorable tolerance profile among patients with myelofibrosis.
Prithviraj Bose, MD, shares...
07/25/2024
Oncology

Advertisement

Jason Westin, MD
Conference Coverage
07/23/2024
Jason Westin, MD, shares expert insight regarding CAR T-cell therapy as standard of care treatment for patients with early relapsed large B-cell lymphoma at the 2024 Pan Pacific Lymphoma Conference.
Jason Westin, MD, shares expert insight regarding CAR T-cell therapy as standard of care treatment for patients with early relapsed large B-cell lymphoma at the 2024 Pan Pacific Lymphoma Conference.
Jason Westin, MD, shares expert...
07/23/2024
Oncology

Advertisement